Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Mesenchymal Stem Cells for Parkinson's Disease
NCT04506073Phase 2Completed
- Sponsor
- Mya Schiess
- Start
- Nov 2020
- Primary completion
- Jul 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MSV alogénicas in Parkinson's disease (PD) (3 arms), sponsored by Mya Schiess. Primary endpoint: Proportion of Participants Achieving a >=5-point Improvement on MDS-UPDRS Part III at Week 62. Started Nov 2020; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04506073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506073.